In 2023, BridgeBio announced positive results from ATTRibute-CM, a Phase 3 study of acoramidis in ATTR cardiomyopathy (ATTR-CM). For patients with ATTR-CM, TTR stabilization offers the chance to both preserve the cardio-protective benefits of TTR and address the root cause of disease. Acoramidis (AG10) is an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR).